Please enter your login details

Professional

Continuous Subcutaneous Insulin Infusion / Insulin Pump Therapy

 “Insulin Pump Therapy” should be considered as a treatment option for people with type 1 diabetes for whom multiple dose insulin therapy has failed and who have the commitment and competence to use CSII therapy effectively. (Updated 2008).

 

Continuous subcutaneous insulin infusion (CSII or ‘insulin pumps’) therapy is recommended as a treatment option for adults and children 16 years and older with Type 1 diabetes mellitus

Pump

 

Assessment Criteria

 

Across Leicester, Leicestershire and Rutland there are over 150 adult patients, currently having insulin pump therapy, with enormous benefits. Our assessment criteria for inclusion of patients is the following:
 

  • Must be above 16 years of age
  • Attempts to achieve target haemoglobin A1c (HbA1c) levels with multiple daily injections (MDIs) results in the person experiencing severe hypoglycaemia. Persistent low blood glucose can have a dramatic affect on the person’s quality of life.

Or

  • Hba1c levels have remained high on multiple injection therapy even after regular support from healthcare professionals including Structured Education (ie DAFNE) and attempts at self management.

 

  • When a child under 12 is struggling with multiple daily injections CSII may also be considered.

 

CSII is not recommended for patient with Type 2 Diabetes

 


What happens if a patient is recommended Pump Therapy

 

Assessment

Our consultant diabetologists, and diabetes specialist nurse.(DSN) carry out the assessment for insulin pump therapy.

Education
The patient is offered intense education input prior to being recommended for pump therapy, for example DAFNE, which is now available and in mainstream funding.

Trial
Following a positive assessment, the patient is then offered a trial of a pump from Roche which are the preferred suppliers in Leicestershire, although alternative suppliers are available.

After care
Once this trial of 1 month is achieved, the patient is regularly followed up to assess biomedical measures and quality of life.
 

More information


Link to the NICE website to Technology Appraisal Guidance, Guidance on the Use of Continuous Subcutaneous Insulin Infusion for Diabetes.